Beyond Air (XAIR) Corporate presentation summary

Technology and product innovation

• LungFit PH is the only FDA- and CE-marked tankless system generating unlimited nitric oxide (NO) from ambient air, eliminating the need for tanks or chemicals.

• Patented Plasma Pulse Technology enables continuous NO generation with built-in safety features and simplified workflows.

• LungFit PH II, pending FDA approval, adds external transport capability, expanding use to air and ground transport.

• The platform supports future expansion into additional hospital and at-home NO applications, including investigational LungFit PRO and GO.

Market opportunity and commercial traction

• U.S. addressable market exceeds $350M, with global opportunity over $1B upon LungFit PH II approval.

• 45 U.S. hospitals contracted, with a 90%+ contract renewal rate and growing international distributor presence in 40+ countries.

• Contracts with major GPOs and access to 7,000+ hospitals nationwide, plus 170 VA Medical Centers.

• Anticipated FDA approval of LungFit PH II could unlock full market access and sole-source provider status at large hospital systems.

Clinical focus and regulatory status

• LungFit PH is FDA-approved for treating hypoxic respiratory failure in term and near-term neonates and CE-marked for peri- and post-operative pulmonary hypertension.

• LungFit PH II is under FDA review for expanded transport indications.

• Pipeline includes investigational high-concentration NO devices for hospital and at-home use, targeting unmet needs like NTM-PD and refractory lung infections.